Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordan Marcou

Physician Assistant Trumbull, CT Physician Assistant

NPI 1154834786 CMS profile 10520472

5520 Park Ave, Trumbull, CT 06611

Open in the dashboard

General payments

$44,235

1,760 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordan Marcou of Trumbull, CT is reported in the CMS Open Payments database as having received $44,235 across 1,760 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,778 373
2024 General $7,037 310
2023 General $15,065 399
2022 General $7,999 337
2021 General $6,356 341

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Marcou
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jordan Marcou were reported at $7,778. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jordan Marcou Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $6,356 $132 $37–$438 $132
2022 $7,999 $155 $48–$522 $149
2023 $15,065 $167 $52–$557 $160
2024 $7,037 $178 $55–$600 $164
2025 $7,778 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Idorsia Pharmaceuticals US Inc $7,832 28 payments
  2. AbbVie, Inc. $4,353 208 payments
  3. ITI, Inc. $4,323 156 payments
  4. Otsuka America Pharmaceutical, Inc. $3,607 155 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $3,206 173 payments
  6. Lundbeck LLC $2,675 124 payments
  7. Teva Pharmaceuticals USA, Inc. $2,544 117 payments
  8. Alkermes, Inc. $2,505 121 payments
  9. Neurocrine Biosciences, Inc. $2,478 103 payments
  10. Corium, Inc. $1,898 90 payments
  11. Other $8,813 485 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $36,657 1,744 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,793 3 payments
  3. Travel and Lodging $1,709 5 payments
  4. Consulting Fee $720 1 payment
  5. Education $357 7 payments
Products named General payments · program years 2021–2025
  1. QUVIVIQ $7,832 28 payments
  2. CAPLYTA $3,539 126 payments
  3. REXULTI $3,098 129 payments
  4. VRAYLAR $3,024 139 payments
  5. TRINTELLIX $2,421 139 payments
  6. INGREZZA $2,077 82 payments
  7. LYBALVI $1,968 89 payments
  8. Azstarys $1,898 90 payments
  9. ARISTADA Cns $1,674 80 payments
  10. ARISTADA Cns $1,674 80 payments
  11. Other $24,490 1,250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,389

Median for Physician Assistant: 241

Drug cost

$270,360

Median for Physician Assistant: $4,110

Branded share of claims

26.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 34 $49,873
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 218 $39,392
Trintellix Vortioxetine Hydrobromide Brand 34 $35,535
Vraylar Cariprazine Hcl Brand 12 $27,865
Belsomra Suvorexant Brand 46 $20,945
Secuado Asenapine Brand 12 $19,441
Quviviq Daridorexant Hcl Brand 22 $10,924
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 15 $7,359
Vyvanse Lisdexamfetamine Dimesylate Brand 16 $6,232
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 117 $4,205

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$41,165

Medicare's payments for the services billed

Medicare patients

89

Average age 68

Services billed

833

44 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Depression 62%
Arthritis 43%
Diabetes 27%
Ischemic heart disease 24%
Osteoporosis 20%
COPD 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$932 — —
REXULTI
$913 34 —
VRAYLAR
$737 12 —
Azstarys
$573 — —
TRINTELLIX
$551 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,760 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record